A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors

Inclusion Criteria: 1. The subjects have been fully informed of the possible risks and benefits of participating in the study and have signed the informed consent form; 2. Age 18-70 years; 3. Immunohistochemistry of tumor tissue samples indicates Claudin18.2 positive ; 4. Recurrent or metastatic advanced solid tumors (including advanced gastric cancers and non-gastric cancers) and have been failed to prior lines of systemic treatment 5. According to the RECIST v1.1, at least one measuable tumor lesion; 6. ECOG performance status score of 0-1; 7. Expected survival ≥ 3 months; 8. Subjects should have adequate organ functions before screening and treatment. 9. Women of childbearing age must have a negative blood pregnancy test; subjects of childbearing potential must use effective contraception for ≥ 1 year after the final study treatment. Exclusion Criteria: 1. Previous CAR-T cell therapy or other cell therapies or therapeutic tumor vaccination against any target; 2. Any previous therapy targeting Claudin18.2; 3. Prior antitumor therapy with insufficient washout period; 4. Pregnant or lactating women; 5. Brain metastases with central nervous system symptoms; 6. Uncontrolled diabetes; 7. Oxygen is required to maintain adequate blood oxygen saturation; 8. Gastric perforation, pyloric obstruction, complete biliary obstruction, complete or incomplete intestinal obstruction requiring clinical intervention, or pleural effusion or peritoneal effusion requiring clinical intervention; 9. Clinically significant liver disorders (including liver cirrhosis, active viral hepatitis or other hepatitis); 10. HIV, Treponema pallidum or HCV serologically positive; 11. Severe underlying disease 12. New York Heart Association (NYHA) Class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) \< 50%; unstable angina, myocardial infarction or coronary artery bypass grafting (CABG) in the past 6 months; history of severe non-ischemic cardiomyopathy; or severe uncontrolled arrhythmia; 13. Any condition that, in the opinion of the investigator, will make the subject unsuitable for participation in this study.